We would love to hear your thoughts about our site and services, please take our survey here.
LL
Surrey pays more in death duties than any other region in Britain, with inheritance-tax-paying residents of the historic home county forking out around £234,000 on average.
More than 1,100 families of Britain’s “inheritance tax capital” paid £259m in IHT during 2017-18, the latest data available from HM Revenue & Customs showed.
Surrey contributed more in death duties than Scotland, where 1,032 estates raised £209m. The county's contribution was larger than those of Wales and Northern Ireland combined where a total of 609 families paid £82m in Wales in while 166 estates paid £25m in Northern Ireland.
meanwhile its envisaged ... share holders in Scancell could be on the hook and beat Surrey .. if the age of the shareholders is considered
talking about planning ref Flu ....
i see the telegraph has picked up on
Hospitals have been ordered to ration prescriptions of the coronavirus “wonderdrug” Remdesivir after a shortage has left trusts without enough to go around.
Doctors have been told they must only give the drug to early-stage coronavirus patients, not to people who have already been admitted to intensive care units and placed on a ventilator.
Grace I have already said you have efficacy and a safety profile so why don't you Invest in it ........... ? to find the optimal dosing structure ... why stop the trial ? you are looking at it the wrong way ....
just a reminder of what i posted ............. before you sell ....... please read
RE: Trinity14 Sep 2020 09:26
RE: Blockbusters inc10 Sep 2020 12:51
who decides the asset Value ? for your NPV calculation ?
you have no cash inflows or outflows .. to even asses what the capital value is ...
what happens if predicted efficacy is achieved or surpassed ?
what added value is then placed on the Modi2 ? and Modi3 programs
what added value is placed on a Successful phase 1/2 of Covid if Scancells can prove its T cells knock out Virus infected cells and indeed the virus itself without neutralizing antibodies ? what happens if the vaccine really does protect the over 55's with far higher efficacy score than any other
that would i suggest would prompt a new Flu vaccine developed around Immunobody
Scancells appears to have solved the Ichor related adverse events (90% in SCIB1) which spurs the second Mark two immunobody "nano" able to treat 90% instead of 45 % of population .. what is the asset value ?
what Value is placed on each of the Glycan Mabs and Avidmab itself
what value is placed on Mab 2811 ?
what Value is placed on Scancells TCR research and the fact that "specific " staff are still being retained ?
what value is being placed on the immunobody platform if both Scib1 and 2 complete trials and hit end points
that then leads on to the Karolinska Institutet ... they are rather clever people ... why did they extend the collaboration .. as they clearly are on to something ...
Trinity is a snap shot and taken with a throw away camera ........... and does not take into account ....... "effect" of the flash
if they did it would run to pages ... and would require Ernst and Young
ATB
The challenge for a vaccine approach is that we still do not know which parts of the host immune response are the most important for vaccine efficacy.
Scancell understood that so targets multiple parts of the Virus .. but with T cells as well as Antibodies
Scancell is skilled in the Art of Cancer Vaccines ........... which is the most difficult vaccine to build because Cancer has already "escaped" the immune system so to engage it you must produce T cells of a higher performance than you body naturally produces because those T cells also have To flip the environment that the cancer has hijacked ..........and the other is HIV because of its super high mutation rate.
Right now, there is a scramble for a vaccine against COVID-19. Many would question why big pharmaceutical companies don’t invest enough in developing vaccines until it is too late.
A vaccine could be a very promising approach to tackle COVID-19. Indeed several experimental vaccines have been developed at breakneck speed and have rapidly entered clinical trials. The challenge for a vaccine approach is that we still do not know which parts of the host immune response are the most important for vaccine efficacy. Because this is a newly emerging virus, it would not have been possible to generate an effective vaccine prior to the pandemic.
As a virologist by training, what does this pandemic tell you?
Pandemics have occurred throughout human history and they are inevitable. In this case, it appears that a virus, which normally resides in bats, was transmitted either directly or indirectly to humans and has spread quickly across the globe. Densely packed human populations and extensive global travel networks have certainly contributed to the pace at which this pandemic has progressed.
Disclaimer: Roche is not actively engaged in vaccine research and development activities for SARS-CoV-2.
https://www.roche.com/strongertogether/john-young-cornavirus-research.htm
the reason why Scancell could take market share is because it can specifically activate the immune system to potentially sterilize the virus giving those that could fall victim a fighting chance and potentially have an effective response against mutations
If you read up on the way the virus evades the immune system just antibodies alone can be circumnavigated by the virus jumping cell to cell potentially weakening the effects of just the s spike protein antibody vaccines. Indeed with this weakening of the vaccine over time could render those that would get a bad response no better off ....
obviously the bulk of this data is coming out now, SNG Covid trial highlighting this in a big way
ATB